Read More

NRx Pharmaceuticals Presents Landmark Trial Of NRX-101 In Suicidal Bipolar Depression At The ASCP Annual Meeting: NRX-101 Is The First Oral Antidepressant Demonstrated To Reduce Suicidality In Bipolar Depression

Poster presentation of "A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavior"NRX-101

NRXP

Read More

Entourage Health Cannabis Reports 9% YoY Increase In Q1 Revenue, Positive EBITDA And ‘Substantial Growth’

Canadian cannabis producer and distributor Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE:4WE) announced on Tuesday its first quarter financial results for the three months ended March 31, 2024. The Toronto-based company reported a total revenue of CA$16.4 million ($12 million) (net revenue of CA$12.7 million, before excise duties and discounts), representing a 9% year-over-year increase. "Entourage's first quarter results are a testament to our robust financial health and strategic approach to business operations, positioning us for success throughout 2024," George Scorsis, the company's chair and CEO, said. "With defined infrastructure and supply agreements in place, we are well-positioned to continue delivering the accelerated growth we have already seen develop in Q1."

ETRGF